Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer

Nishida, Naohiro; Sakai, Daisuke; Satoh, Taroh

International Journal of Clinical Oncology, 2024, 29(9), 1237-1243

アクセス数:380件（2025-07-11 18:36 集計）

固定URL: https://hdl.handle.net/11094/96463

閲覧可能ファイル 

ファイル フォーマット 利用条件 サイズ 閲覧回数 利用開始日 説明 information
IntJClinOncol_s10147_024_02500_8 pdf なし 0.99 MB 147 2024.06.27  
Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル
Treatment strategy for HER2-negative advanced gastric cancer: salvage-line strategy for advanced gastric cancer
著者
NRID
1000050588118 1000050588118
researchmap permalink
naohiro_nishida naohiro_nishida
著者名
Nishida, Naohiro
NRID
1000010621071 1000010621071
著者名
Sakai, Daisuke
NRID
1000040368303 1000040368303
ORCID
0000-0002-4615-2638 0000-0002-4615-2638
researchmap permalink
TarohSatoh TarohSatoh
Scopus Author ID
12040860900 12040860900
著者名
Satoh, Taroh
キーワード等
Advanced gastric cancer
Anti-VEGF treatment
Immune checkpoint inhibitor (ICI)
Later-line treatment
Tyrosine kinase inhibitors (TKIs)
内容
The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02500-8.
抄録
After immune checkpoint inhibitor (ICI) comes into third-line treatment of advanced gastric cancer, the therapeutic strategy has been dramatically changed. Recent first-line regimen, which consists of ICI and chemotherapeutic agents, prolonged progression-free survival, and subsequent treatment options enabled continuous treatment beyond second-line therapy. Moreover, the advent of vascular endothelial growth factor (VEGF)-targeted agents including angiogenesis inhibitors and TKIs provides an opportunity of considering the interaction between ICI and anti-VEGF agents, and facilitating novel treatment proposal. Although clinical benefit of prolonged VEGF blockade after disease progression has not been confirmed in gastric cancer, combination therapy of cytotoxic agents and anti-VEGF agent, such as irinotecan plus ramucirumab demonstrated favorable objective response rate and progression-free survival in third- or later-line setting. In this review, we discuss recent progress and future directions of later-line treatments of HER2-negative advancer gastric cancer.
出版者
Springer
収録物名
International Journal of Clinical Oncology
巻(号)
29(9)
ページ
1237-1243
刊行年月
2024-05-11
言語
英語
ハンドルURL
https://hdl.handle.net/11094/96463
PISSN
13419625
eISSN
14377772
関連情報 (isIdenticalTo)
DOI (出版社版)
https://doi.org/10.1007/s10147-024-02500-8
アクセス権
open access
権利情報
This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ
Version of Record
カテゴリ
学術雑誌論文 Journal Article